ACC 2022: Late-breaking Science Video Collection

Published: 05 April 2022

  • Views:

    Views Icon 3671
  • Likes:

    Heart Icon 7

Overview

Full programme

View Transcript

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data. 

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.

Part 3

Expert Interviews

Faculty Biographies

Frederik Zimmermann

Frederik Zimmermann

Dr Frederik Zimmermann is an interventional cardiologist at Catharina Hospital, Eindhoven, NL.

View full profile

Transcript

- Hi, I'm Frederik Zimmermann. I'm from the Catharina Hospital in Eindhoven in the Netherlands and I will talk about the quality of life analysis, the FAME 3 Trial.

Study Rationale

So, previous studies have shown that revascularisation improves quality of life and more so after CABG than PCI. However, previous trials did not use FFR to guide PCI and did not use second-generation drug-eluting stents, both of which have been shown to improve outcome. For that reason, the FAME 3 study was conducted, which was an investigator-initiated, multicentre, international, randomised controlled trial in 48 sites worldwide, comparing FFR-guided PCI with CABG in patients with three-vessel disease. As presented by Dr Fearon last year at TCT, and also published in New England Journal of Medicine, PCI did not meet noninferiority with respect to MACE at one year. However, if you look at the event rates compared to previous trials, then the event rates are lower and the differences between PCI and CABG narrow. So in light of the smaller differences in event rates, the quality of life angina status, as well as working status, becomes much more important for clinical decision making.

Study Design and Patient Cohort

So, for this quality of life analysis, our primary endpoint was the EQ-5D summary index at one year. We assessed quality of life at baseline, one month and 12 months, as well as the Visual Analogue Scale of the EQ-5D. Angina status and working status were also assessed at that point but also at six months.

Key Findings

We found that quality of life at one year was identical between the FFR-guided PCI group and the CABG group. However, FFR-guided PCI resulted in faster improvement of quality of life. We also found that the angina was dramatically decreased over both forms of revascularisation, with no differences at 12 months and working. And patients in the CABG arm worked less at one month. Interestingly, if we looked at a pre-specified subgroup analysis of patients younger than 65 years old at time of randomisation, we found that patients in the CABG group worked less at one month but also at six months and 12 months.

Take-home Messages for Clinicians

In light of the low event rates, it's all about shared decision-making with the patients. And we now have the data. We're very confident that the quality of life improves faster after FFR-guided PCI, with no differences also with respect to angina at one year.

Further Study Required

It will also be important to look at longer follow-up. So, we will also follow patients for up to five years. We will do the quality of life analysis at three and five years. I have to say, though, that in previous studies such as SYNTAX and FREEDOM, the main findings did not change that much beyond one year, with respect to quality of life.